Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity of $112.77M in Q2 FY2026

Q2 FY2026 total equity was $112.77M.

Context

  • Total equity amounted to 87.9% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$112.77M-15.0% QoQ
Last fiscal yearDec 2025
$150.79M+142.7% YoY
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+142.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
150.79M USD
Year-over-year change
+142.7%
1-year CAGR
+142.7%

Total Equity vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Total equity amounts to 87.9% of total assets for ATTO, versus a peer median of 77.8%.
ATTO Competitors
Total Equity for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ORKAOruka Therapeutics, Inc.Sep 2026$1.2B USD+145.9%+124.6%97.2%
ALMSAlumis Inc. Common StockJun 2026$452.16M USD-6.8%—80.7%
EVMNEvommune, Inc.Mar 2026$304.56M USD+292.5%—94.4%
MLTXMoonLake ImmunotherapeuticsMar 2026$254.02M USD-38.4%+64.2%63.4%
ZURAZura Bio LimitedMar 2026$216.9M USD+43.3%—94.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€146.93M EUR——88.7%
ACRSAclaris Therapeutics, Inc.Mar 2026$143.65M USD-0.3%-19.5%72.3%
ATTOAttovia Therapeutics, Inc.Jun 2026$112.77M USD——87.9%
QTTBQ32 Bio Inc.Mar 2026$46.31M USD+1253.8%—72.7%
CNTBConnect Biopharma Holdings LimitedDec 2025$41.98M USD-54.5%-35.6%74.9%
ANABAnaptysBio, Inc.Mar 2026$12.75M USD-62.5%-47.8%3.9%
Peer median (excluding ATTO) —-0.3%-19.5%77.8%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.